Cover Image
市場調查報告書

CardioVascular BioTherapeutics, Inc.:產品臨床實驗分析

CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 200935
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
CardioVascular BioTherapeutics, Inc.:產品臨床實驗分析 CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014
出版日期: 2014年04月30日 內容資訊: 英文 27 Pages
簡介

CardioVascular BioTherapeutics, Inc.是開發心血管疾病治療新蛋白質醫藥品的生技藥品企業。

本報告針對CardioVascular BioTherapeutics, Inc.治療藥開發臨床實驗現況與各開發階段比較分析、提供藥劑標的、作用程序、投藥過程、分子種類分類治療藥評價、最新企業新聞發表、後期階段與中止方案相關資料。

CardioVascular BioTherapeutics, Inc.基本情報

CardioVascular BioTherapeutics, Inc.概要

  • 主要情報
  • 企業情報

CardioVascular BioTherapeutics, Inc.:R&D概要

  • 主要治療範圍

CardioVascular BioTherapeutics, Inc.:臨床實驗回顧

  • 開發階段分類臨床實驗產品
  • 單劑產品

CardioVascular BioTherapeutics, Inc.:臨床實驗產品概況

  • 測試階段臨床實驗產品
    • 第II期產品/併用療法模式
    • 第I期產品/併用療法模式

CardioVascular BioTherapeutics, Inc.:藥劑檔案

  • CVBT-141A
  • CVBT-141B
  • CVBT-141H
  • CVBT-141C

CardioVascular BioTherapeutics, Inc.:臨床實驗分析

  • 標的分類
  • 投藥通路分類
  • 分子種類分類
  • 作用排序分類

CardioVascular BioTherapeutics, Inc.:最近臨床實驗動向

CardioVascular BioTherapeutics, Inc.:暫停方案

CardioVascular BioTherapeutics, Inc.:開發中止的臨床實驗產品

  • 開發中止的臨床實驗產品檔案
    • CVBT-141E

CardioVascular BioTherapeutics, Inc.:企業發表

CardioVascular BioTherapeutics, Inc.:總公司與子公司所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04819CDB

Global Markets Direct's, 'CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the CardioVascular BioTherapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CardioVascular BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CardioVascular BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CardioVascular BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CardioVascular BioTherapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate CardioVascular BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CardioVascular BioTherapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CardioVascular BioTherapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CardioVascular BioTherapeutics, Inc. Snapshot
    • CardioVascular BioTherapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • CardioVascular BioTherapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CardioVascular BioTherapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CardioVascular BioTherapeutics, Inc. - Pipeline Products Glance
    • CardioVascular BioTherapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • CardioVascular BioTherapeutics, Inc. - Drug Profiles
    • CVBT-141A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141H
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141C
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CardioVascular BioTherapeutics, Inc. - Pipeline Analysis
    • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Target
    • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Route of Administration
    • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Molecule Type
    • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action
  • CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates
  • CardioVascular BioTherapeutics, Inc. - Dormant Projects
  • CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
    • CVBT-141E
  • CardioVascular BioTherapeutics, Inc. - Company Statement
  • CardioVascular BioTherapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CardioVascular BioTherapeutics, Inc., Key Information
  • CardioVascular BioTherapeutics, Inc., Key Facts
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Indication, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014
  • CardioVascular BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014
  • CardioVascular BioTherapeutics, Inc. - Phase II, 2014
  • CardioVascular BioTherapeutics, Inc. - Phase I, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Target, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014
  • CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates, 2014
  • CardioVascular BioTherapeutics, Inc. - Dormant Developmental Projects,2014
  • CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Indication, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014
  • CardioVascular BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Target, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • CardioVascular BioTherapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top